VERA

Vera Therapeutics, Inc.

Price Chart

Latest Quote

$33.67

-0.57 (-1.66%)

Current Price

Previous Close	$34.24
Open	$34.49
Day High	$34.70
Day Low	$32.95
Volume	933,656

Fetched: 2026-06-17T12:50:29

Stock Information

Shares Outstanding	71.78M
Total Debt	$76.89M
Cash Equivalents	$596.76M
Net Income	$-368.95M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$2.42B
EPS (TTM)	$-5.54
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.90B
Income	$-368.95M
Book/sh	$6.97
Cash/sh	$8.31
Employees	339

Financial Ratios

Quick Ratio	13.30
Current Ratio	13.64
Debt/Eq	15.39

Returns & Margins

ROA	-38.90%
ROE	-71.32%

Ownership

Insider Ownership	0.87%
Institutional Ownership	110.51%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-8.86
P/B	4.83

Analyst Data

Recommendation	strong_buy
Target Price	$78.00

Technical Indicators

SMA20	$nan
SMA50	$nan
SMA200	$nan
RSI	49.88
ATR	nan

Shares Float	52.06M
Short Float	17.19%
Short Ratio	10.86
Volatility	0.95
Rel Volume	0.89

Performance History

Week	nan%
Month	nan%
Quarter	nan%
6 Months	nan%
YTD	nan%
Year	nan%
3 Years	nan%
5 Years	nan%
10 Years	nan%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-16	$nan	933,656
2026-06-15	$34.24	559,700
2026-06-12	$34.26	901,700
2026-06-11	$33.65	884,100
2026-06-10	$31.62	697,200
2026-06-09	$31.81	913,100
2026-06-08	$31.75	698,900
2026-06-05	$32.29	1,515,700
2026-06-04	$33.38	2,982,000
2026-06-03	$31.27	991,400
2026-06-02	$31.26	1,716,100
2026-06-01	$33.94	921,900
2026-05-29	$35.52	1,035,600
2026-05-28	$35.86	1,717,000
2026-05-27	$34.27	659,500
2026-05-26	$34.34	682,100
2026-05-22	$34.04	448,600
2026-05-21	$34.35	527,700
2026-05-20	$34.62	870,200
2026-05-19	$33.25	1,285,000
2026-05-18	$34.35	1,597,300

About Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

📰 Latest News

Will FDA Alignment on Atacicept’s eGFR Plan Reshape Vera Therapeutics’ (VERA) IgA Nephropathy Narrative

Simply Wall St. • 2026-06-08T20:10:51Z

A Look At Vera Therapeutics (VERA) Valuation After FDA Alignment On Accelerated IgA Nephropathy Trial Analysis

Simply Wall St. • 2026-06-08T15:11:30Z

Sector Update: Healthcare Stocks Softer Late Afternoon

MT Newswires • 2026-06-02T19:45:10Z

Vera Therapeutics Moves Closer To Full Approval For Kidney Disease Drug After FDA Alignment

Stocktwits • 2026-06-02T16:51:46Z

Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing

Motley Fool • 2026-05-26T18:49:42Z

The Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-Up

Simply Wall St. • 2026-05-11T01:09:50Z

Is Vera Therapeutics (VERA) Still Attractive After An 87% One Year Share Price Surge

Simply Wall St. • 2026-04-10T10:07:48Z

These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target

24/7 Wall St. • 2026-04-01T11:35:58Z

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding

Motley Fool • 2026-03-21T22:43:15Z

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Motley Fool • 2026-03-21T22:33:31Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$7,531,000	$7,626,000	$3,786,000	$992,000
Total Expenses	$315,473,000	$167,170,000	$102,012,000	$90,903,000
Other Income Expense	$-1,089,000	$1,935,000	$1,830,000	$1,090,000
Other Non Operating Income Expenses	$-1,089,000	$1,935,000	$1,830,000	$1,899,000
Net Non Operating Interest Income Expense	$16,948,000	$13,088,000	$4,193,000	$758,000
Interest Expense Non Operating	$7,531,000	$7,626,000	$3,786,000	$992,000
Operating Expense	$315,473,000	$167,170,000	$102,012,000	$90,903,000
General And Administrative Expense	$100,217,000	$40,998,000	$23,787,000	$21,910,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-299,615,000	$-152,148,000	$-95,990,000	$-89,056,000
Net Interest Income	$16,948,000	$13,088,000	$4,193,000	$758,000
Interest Income	$24,479,000	$20,714,000	$7,979,000	$1,750,000
Normalized Income	$-299,615,000	$-152,148,000	$-95,990,000	$-88,416,890
Net Income From Continuing And Discontinued Operation	$-299,615,000	$-152,148,000	$-95,990,000	$-89,056,000
Total Operating Income As Reported	$-315,473,000	$-167,170,000	$-102,012,000	$-90,903,000
Net Income Common Stockholders	$-299,615,000	$-152,148,000	$-95,990,000	$-89,056,000
Net Income	$-299,615,000	$-152,148,000	$-95,990,000	$-89,056,000
Net Income Including Noncontrolling Interests	$-299,615,000	$-152,148,000	$-95,990,000	$-89,056,000
Net Income Continuous Operations	$-299,615,000	$-152,148,000	$-95,990,000	$-89,056,000
Pretax Income	$-299,614,000	$-152,147,000	$-95,989,000	$-89,055,000
Interest Income Non Operating	$24,479,000	$20,714,000	$7,979,000	$1,750,000
Operating Income	$-315,473,000	$-167,170,000	$-102,012,000	$-90,903,000
Special Income Charges	-	-	-	$0
Per Share
Diluted EPS	$-4.66	$-2.75	$-2.25	$-3.35
Basic EPS	$-4.66	$-2.75	$-2.25	$-3.35
Other
Tax Effect Of Unusual Items	$0	$0	$0	$-169,890
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-291,615,000	$-144,416,000	$-92,182,000	$-87,254,000
Reconciled Depreciation	$468,000	$105,000	$21,000	$-846,000
EBITDA (Bullshit earnings)	$-291,615,000	$-144,416,000	$-92,182,000	$-88,063,000
EBIT	$-292,083,000	$-144,521,000	$-92,203,000	$-88,063,000
Diluted Average Shares	$64,233,814	$55,326,680	$42,707,072	$26,570,676
Basic Average Shares	$64,233,814	$55,326,680	$42,707,072	$26,570,676
Diluted NI Availto Com Stockholders	$-299,615,000	$-152,148,000	$-95,990,000	$-89,056,000
Tax Provision	$1,000	$1,000	$1,000	$1,000
Research And Development	$215,256,000	$126,172,000	$78,225,000	$68,993,000
Selling General And Administration	$100,217,000	$40,998,000	$23,787,000	$21,910,000
Other Gand A	$100,217,000	$40,998,000	$23,787,000	$21,910,000
Total Unusual Items	-	-	$-47,000	$-809,000
Total Unusual Items Excluding Goodwill	-	-	$-47,000	$-809,000
Gain On Sale Of Security	-	-	$-47,000	$-809,000
Gain On Sale Of Business	-	-	-	$0
Restructuring And Mergern Acquisition	-	-	-	-

Fetched: 2026-06-10

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$604,521,000	$577,155,000	$101,685,000	$76,908,000
Total Assets	$734,733,000	$655,681,000	$175,546,000	$131,435,000
Total Non Current Assets	$5,850,000	$4,463,000	$3,523,000	$5,737,000
Other Non Current Assets	$2,553,000	$131,000	$482,000	$513,000
Current Assets	$728,883,000	$651,218,000	$172,023,000	$125,698,000
Other Current Assets	$2,535,000	$1,383,000	$2,237,000	$719,000
Prepaid Assets	$8,474,000	$5,210,000	$8,558,000	$10,326,000
Receivables	$3,285,000	$3,773,000	$512,000	-
Accrued Interest Receivable	$3,285,000	$3,773,000	$512,000	-
Cash Cash Equivalents And Short Term Investments	$714,589,000	$640,852,000	$160,716,000	$114,653,000
Cash And Cash Equivalents	$354,725,000	$92,646,000	$45,681,000	$43,459,000
Cash Equivalents	$350,106,000	$89,727,000	-	-
Cash Financial	$4,619,000	$2,919,000	-	-
Investmentin Financial Assets	-	-	-	$58,000
Non Current Prepaid Assets	-	-	-	-
Debt
Total Debt	$77,306,000	$54,638,000	$53,708,000	$31,286,000
Long Term Debt And Capital Lease Obligation	$76,757,000	$53,155,000	$51,272,000	$28,641,000
Long Term Debt	$74,838,000	$50,687,000	$49,877,000	$24,810,000
Current Debt And Capital Lease Obligation	$549,000	$1,483,000	$2,436,000	$2,645,000
Net Debt	-	-	$4,196,000	-
Liabilities
Total Liabilities Net Minority Interest	$130,212,000	$78,526,000	$73,861,000	$54,527,000
Total Non Current Liabilities Net Minority Interest	$76,757,000	$53,155,000	$51,558,000	$28,927,000
Current Liabilities	$53,455,000	$25,371,000	$22,303,000	$25,600,000
Other Current Liabilities	$1,367,000	$1,753,000	-	-
Payables And Accrued Expenses	$51,539,000	$22,135,000	$19,867,000	$22,955,000
Payables	$21,901,000	$7,882,000	$13,044,000	$14,771,000
Accounts Payable	$21,898,000	$7,665,000	$11,118,000	$11,991,000
Other Non Current Liabilities	-	-	-	-
Equity
Common Stock Equity	$604,521,000	$577,155,000	$101,685,000	$76,908,000
Total Equity Gross Minority Interest	$604,521,000	$577,155,000	$101,685,000	$76,908,000
Stockholders Equity	$604,521,000	$577,155,000	$101,685,000	$76,908,000
Gains Losses Not Affecting Retained Earnings	$786,000	$393,000	$251,000	$-224,000
Other Equity Adjustments	$786,000	$393,000	$251,000	$-224,000
Retained Earnings	$-760,865,000	$-461,250,000	$-309,102,000	$-213,112,000
Other
Ordinary Shares Number	$71,267,429	$63,559,858	$44,452,161	$27,800,861
Share Issued	$71,267,429	$63,559,858	$44,452,161	$27,800,861
Tangible Book Value	$604,521,000	$577,155,000	$101,685,000	$76,908,000
Invested Capital	$679,359,000	$627,842,000	$151,562,000	$101,718,000
Working Capital	$675,428,000	$625,847,000	$149,720,000	$100,098,000
Capital Lease Obligations	$2,468,000	$3,951,000	$3,831,000	$6,476,000
Total Capitalization	$679,359,000	$627,842,000	$151,562,000	$101,718,000
Additional Paid In Capital	$1,364,529,000	$1,037,948,000	$410,492,000	$290,216,000
Capital Stock	$71,000	$64,000	$44,000	$28,000
Common Stock	$71,000	$64,000	$44,000	$28,000
Long Term Capital Lease Obligation	$1,919,000	$2,468,000	$1,395,000	$3,831,000
Current Capital Lease Obligation	$549,000	$1,483,000	$2,436,000	$2,645,000
Current Accrued Expenses	$29,638,000	$14,253,000	$6,823,000	$8,184,000
Dueto Related Parties Current	$3,000	$217,000	$1,926,000	$2,780,000
Net PPE	$3,297,000	$4,332,000	$3,041,000	$5,224,000
Gross PPE	$3,297,000	$4,332,000	$3,041,000	$5,224,000
Other Properties	$1,374,000	$960,000	$92,000	$51,000
Buildings And Improvements	$1,923,000	$3,372,000	$2,949,000	$5,173,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$359,864,000	$548,206,000	$115,035,000	$71,194,000
Preferred Stock	-	$0	$0	$0
Non Current Accrued Expenses	-	$0	$286,000	$286,000
Investments And Advances	-	-	-	$58,000
Available For Sale Securities	-	-	-	$58,000

Fetched: 2026-06-10

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-241,734,000	$-135,651,000	$-92,244,000	$-67,658,000
Operating Activities
Operating Cash Flow	$-241,104,000	$-134,679,000	$-92,181,000	$-67,596,000
Cash Flow From Continuing Operating Activities	$-241,104,000	$-134,679,000	$-92,181,000	$-67,596,000
Operating Gains Losses	-	-	-	-
Investing Activities
Capital Expenditure	$-630,000	$-972,000	$-63,000	$-62,000
Investing Cash Flow	$194,286,000	$-425,029,000	$-39,431,000	$-70,552,000
Cash Flow From Continuing Investing Activities	$194,286,000	$-425,029,000	$-39,431,000	$-70,552,000
Net Other Investing Changes	$-800,000	-	-	-
Financing Activities
Repurchase Of Capital Stock	$0	$-13,000	$0	-
Issuance Of Capital Stock	$300,500,000	$632,537,000	$115,000,000	$86,131,000
Financing Cash Flow	$308,897,000	$606,673,000	$133,541,000	$101,933,000
Cash Flow From Continuing Financing Activities	$308,897,000	$606,673,000	$133,541,000	$101,933,000
Net Other Financing Charges	$-21,922,000	$-39,264,000	$-7,256,000	$-6,097,000
Net Common Stock Issuance	$300,500,000	$632,524,000	$115,000,000	$86,131,000
Common Stock Issuance	$300,500,000	$632,537,000	$115,000,000	$86,131,000
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
Issuance Of Debt	$23,338,000	$0	$24,741,000	$19,816,000
Interest Paid Supplemental Data	$6,720,000	$6,652,000	$3,352,000	$895,000
End Cash Position	$354,725,000	$92,646,000	$45,681,000	$43,752,000
Beginning Cash Position	$92,646,000	$45,681,000	$43,752,000	$79,967,000
Changes In Cash	$262,079,000	$46,965,000	$1,929,000	$-36,215,000
Proceeds From Stock Option Exercised	$6,981,000	$13,413,000	$1,056,000	$2,083,000
Common Stock Payments	$0	$-13,000	$0	-
Net Issuance Payments Of Debt	$23,338,000	$0	$24,741,000	$19,816,000
Net Long Term Debt Issuance	$23,338,000	$0	$24,741,000	$19,816,000
Long Term Debt Issuance	$23,338,000	$0	$24,741,000	$19,816,000
Net Investment Purchase And Sale	$195,716,000	$-424,057,000	$-39,368,000	$-70,490,000
Sale Of Investment	$506,162,000	$278,958,000	$185,562,000	$78,000,000
Purchase Of Investment	$-310,446,000	$-703,015,000	$-224,930,000	$-148,490,000
Net PPE Purchase And Sale	$-630,000	$-972,000	$-63,000	$-62,000
Purchase Of PPE	$-630,000	$-972,000	$-63,000	$-62,000
Change In Working Capital	$22,992,000	$2,660,000	$-5,822,000	$6,747,000
Change In Other Current Liabilities	$-1,483,000	$-2,407,000	$-2,645,000	$-2,602,000
Change In Other Current Assets	$51,000	$351,000	$-262,000	$-111,000
Change In Payables And Accrued Expense	$28,352,000	$3,735,000	$-3,088,000	$17,642,000
Change In Accrued Expense	$14,442,000	$7,188,000	$-2,215,000	$7,036,000
Change In Payable	$13,910,000	$-3,453,000	$-873,000	$10,606,000
Change In Account Payable	$13,910,000	$-3,453,000	$-873,000	$10,606,000
Change In Prepaid Assets	$-3,928,000	$981,000	$173,000	$-8,182,000
Other Non Cash Items	$4,106,000	$2,874,000	$2,550,000	$5,863,000
Stock Based Compensation	$37,926,000	$20,802,000	$11,493,000	$8,887,000
Amortization Of Securities	$-6,981,000	$-8,972,000	$-4,433,000	-
Depreciation Amortization Depletion	$468,000	$105,000	$21,000	$-846,000
Depreciation And Amortization	$468,000	$105,000	$21,000	$-846,000
Net Income From Continuing Operations	$-299,615,000	$-152,148,000	$-95,990,000	$-89,056,000
Unrealized Gain Loss On Investment Securities	-	-	$47,000	$809,000
Depreciation	-	-	$-4,086,000	$-846,000
Net Intangibles Purchase And Sale	-	-	-	$0
Sale Of Intangibles	-	-	-	$0
Gain Loss On Sale Of PPE	-	-	-	$0
Repayment Of Debt	-	-	-	-
Long Term Debt Payments	-	-	-	-
Sale Of PPE	-	-	-	-
Asset Impairment Charge	-	-	-	-

Fetched: 2026-06-10